MAT1a Antisense Inhibition for Metabolic Disease Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic diseases such as obesity, diabetes, and insulin resistance associated with methionine adenosyltransferase 1a (MAT1a) are inadequate in effectively reducing MAT1a expression or activity, leading to insufficient improvements in adiposity, insulin sensitivity, and liver health.
Innovation Solution
The use of MAT1a-specific inhibitors, including nucleic acids, peptides, antibodies, and small molecules, to specifically inhibit MAT1a expression or activity, thereby modulating its levels and improving metabolic health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for metabolic diseases, then MAT1a expression or activity is not effectively reduced, but this results in insufficient improvements in adiposity, insulin sensitivity, and liver health
Solution Approach 1:
The patent employs antisense oligonucleotides with specific chemical modifications (2'-O-methoxyethyl groups, phosphorothioate backbone) to alter the parameters of the therapeutic agent itself, achieving reliable and specific inhibition of MAT1a expression. This molecular-level parameter change enables effective reduction of MAT1a protein levels, directly addressing the contradiction between reliable inhibition and therapeutic benefit.
Solution Approach 2:
The antisense oligonucleotide acts as an intermediary molecule that specifically binds to MAT1a mRNA, preventing its translation into protein. This intermediary mechanism provides reliable and specific inhibition of MAT1a without affecting other metabolic pathways, thereby achieving both reliable inhibition and substantial therapeutic benefit in metabolic disease treatment.
2Productivity
If MAT1a-specific inhibitors are used to reduce MAT1a expression, then adiposity is reduced and insulin sensitivity is enhanced, but this requires development of novel specific inhibitors
Solution Approach 1:
The patent replaces traditional small-molecule inhibitor approaches with nucleic acid-based antisense oligonucleotides. This substitution leverages the specificity of nucleic acid base pairing to achieve precise targeting of MAT1a mRNA, simplifying the development process while delivering significant metabolic health improvements including reduced adiposity and enhanced insulin sensitivity.
Solution Approach 2:
The therapeutic approach is segmented into distinct functional components: the antisense oligonucleotide sequence specifically complementary to MAT1a mRNA, chemical modification groups for stability and specificity, and delivery mechanisms. This segmentation allows for systematic optimization of each component to achieve effective MAT1a inhibition and metabolic improvement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inhibition of MAT1a leads to reduced adiposity, increased adiponectin levels, enhanced insulin sensitivity, and improved fatty liver conditions, providing therapeutic benefits for metabolic disorders.
Implementation Method 1
antisense oligonucleotide (ASO) for MAT1A... MAT1a knockdown
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided herein are methods, compounds, and compositions for reducing expression of MAT1a in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a metabolic disease or disorder in an individual.